TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01894243

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablet dosing
Description: Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD
Study: NCT00265876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000mg/m2 IV weekly
Study: NCT01773850

Intervention type: DEVICE
Intervention: Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner
Description: All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: 100 mg tablet orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
Study: NCT03310749

Intervention type: DRUG
Group type: OTHER
Intervention: Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
Description: A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
Study: NCT04366037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training
Description: Training will be defined by each club coach
Study: NCT03310749

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
Study: NCT04366037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training + proprioceptive exercise in warm-up
Description: Training will be defined by each club coach, adding four proprioceptive exercises in warm-up:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine training + proprioceptive exercise in cool-down
Description: Training will be defined by each club coach, adding four proprioceptive exercises in cool-down:~Exercise Description Duration Antero-posterior bipodal horizontal jump Players will jump forward and backward with both feet together, keeping their hands on their waists 30 seconds Unipodal lateral jump Players will perform single-leg lateral jump on both sides of a previously drawn line on the ground, and keeping their hands on their waists. 30 seconds per limb.~Antero-posterior unipodal horizontal jump Players will jump forward and backward with one foot, keeping their hands on their waists 30 seconds per limb.~Bipodal vertical jump with or whitout ball. Players will perform vertical jumps with both feet carrying a ball in their hands (this added difficulty will be optional). 30 seconds
Study: NCT03156478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital lifestyle intervention group
Description: Intervention with digital application for lifestyle changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined digital and face-to-face lifestyle intervention group
Description: Intervention with digital application and group meetings for lifestyle changes
Study: NCT04620083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Learning Program for Old People with Dementia
Description: The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Learning Program for Old People with Dementia
Description: The program included modalities for reality orientation, daily living skills training, reminiscence therapy, multisensory stimulation, fall prevention program, mindfulness activities, Meridian exercise, brain health program (Four Arts of the Chinese Scholar which referred to zither, go, calligraphy and painting) and health education. It was also agreed that case managers, caregivers, and participants were free to choose these treatments or could be assigned to a treatment regime on a 'mix and match' basis to suit their personality traits for improving their abilities to meet their own needs. This program was developed by the team using Delphi technique.
Study: NCT02719132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin, 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin, 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin, up to 2500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, up to 2500 mg
Study: NCT00704028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Dextran
Description: As determined by the investigator to a maximum cumulative dose of 2,250 mg.
Study: NCT03393156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based metacognitive therapy
Description: Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
Study: NCT03322215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
Study: NCT02422524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: Pretomanid (PA-824) is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
Study: NCT00626561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV twice weekly on days 1 and 15.
Study: NCT03322215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
Study: NCT01340092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Navigator
Description: Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~1. Help family identify key issues they need to address to get their child autism-specific services~2. Help family address barriers to obtaining these services and strategize approaches to overcome them.
Study: NCT03483675

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Therapy
Description: Discontinued IST

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Therapy
Description: Continued IST
Study: NCT00626561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60 mg/m\^2 IV weekly on days 1, 8, 15, and 22.
Study: NCT02308124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine + pyridostigmine
Study: NCT03483675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04931121

Intervention type: DRUG
Intervention: Viscosupplements
Description: Synovial fluid is collected as part of a conventional injection of viscosupplement
Study: NCT03483675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01787175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Medication Manager
Description: A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
Study: NCT00799578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Description: Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
Study: NCT03088761

Intervention type: DEVICE
Intervention: cuffed tracheal tube
Description: the changes in cuff pressure will be determined using a cuff manometer
Study: NCT01663415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral
Study: NCT00896558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
Study: NCT00896558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo
Description: GSK1322322/placebo escalating doses from 500mg to 1500mg
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
Study: NCT00896558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322/placebo and midazolam
Description: GSK1322322/placebo and 5mg midazolam
Study: NCT01301495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANAROSTENT TM covered Esophageal Stent
Description: HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
Study: NCT01139736

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
Study: NCT01886807

Intervention type: DEVICE
Group type: OTHER
Intervention: TrueView PCD Video Laryngoscope

Intervention type: DEVICE
Group type: OTHER
Intervention: TrueView PCD Video Laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueView PCD Video Laryngoscope
Study: NCT01978028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01625143

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02124863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrapulmonary Percussive Ventilation
Description: 20 min IPV freq 300/min, p 10cmH2O
Study: NCT03089203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN cells
Description: autologous CAR T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2/day given over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2/day given over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2/day given over 3 days
Study: NCT03089203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day given over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day given over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day given over 3 days
Study: NCT03454984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: 30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
Study: NCT03803280

Intervention type: PROCEDURE
Intervention: ERAS program
Description: ERAS pathway according to the Spanish Via RICA
Study: NCT00748215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium aluminosilicate anti-diarrheal
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01717326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Elbasvir
Description: Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Elbasvir
Description: Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
Study: NCT02716207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: Radiation Therapy
Study: NCT04629235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wonder around
Description: wonder around after 8 hours of bedrest

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: bedrest
Description: 24 hours of bedrest
Study: NCT03871803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled withdrawal of beta-blockers
Description: Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled withdrawal of beta-blockers
Description: Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)